Bloomberg reports Isomorphic Labs funding talks at $40 billion-plus value
The Alphabet AI drug discovery company is said to be discussing a new round, but Bloomberg says financing has not closed and terms may change.
What Bloomberg reported
Isomorphic Labs is in early talks to raise money at a valuation of at least $40 billion, Bloomberg reported on October 8, citing people familiar with the discussions. One of those people said the possible round could value the Alphabet company at as much as $50 billion. Isomorphic Labs uses AI in drug discovery and was spun out of Google DeepMind. The report concerns a proposed financing, not a new drug approval, clinical result or completed funding round.
The terms are unsettled
Bloomberg explicitly says the financing has not closed and details could change. Neither the $40 billion floor nor the possible $50 billion figure is an announced final valuation. The article does not establish how much cash Isomorphic would raise, who would invest or when a deal might be signed. Those gaps matter because a valuation discussed during negotiations can differ from the terms of a completed transaction. This report is also separate from Isomorphic’s participation in the Biohub biology-data initiative announced October 7; that commitment does not confirm the fundraising terms Bloomberg described.